Wegovy vs. Zepbound
100% Online — No Office Visit Required
Wegovy and Zepbound are the two FDA-approved medications for chronic weight management. Wegovy contains semaglutide; Zepbound contains tirzepatide. Both require provider evaluation.
Zepbound (tirzepatide) has shown higher average weight loss in trials compared to Wegovy (semaglutide). Both are effective and provider-approved programs. The right choice depends on individual response, tolerability, and access.
Side-by-Side Comparison
| Feature | Wegovy (Semaglutide) | Zepbound (Tirzepatide) |
|---|---|---|
| Active ingredient | Semaglutide 2.4mg | Tirzepatide 5–15mg |
| Mechanism | GLP-1 agonist | Dual GLP-1/GIP agonist |
| Average weight loss | ~15% | ~20–22% |
| Dosing | Weekly injection | Weekly injection |
Common Questions
Is Zepbound new?
Yes — Zepbound was approved by the FDA in November 2023 for chronic weight management. Tirzepatide (Mounjaro) had been available for type 2 diabetes since 2022.
Ready to Get Started?
Complete a brief online intake. A licensed provider will review your information and determine if treatment is appropriate for you.
Medical Disclaimer: The information on this page is provided for educational purposes only and does not constitute medical advice. OakMD is a telemedicine platform. All treatments are prescription-based, subject to provider review, and may not be appropriate for all individuals. A licensed provider will evaluate your medical history and determine eligibility. Consult a qualified healthcare professional before starting any new treatment.